Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat (NIC-002)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04644705
Recruitment Status : Recruiting
First Posted : November 25, 2020
Last Update Posted : November 25, 2020
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Charité Research Organisation GmbH

Brief Summary:

Niclosamide is a well-established substance that is a promising candidate for a repurposing approach to treat COVID-19. Niclosamide is currently marketed as a chewing tablet for the treatment of intestinal worm infections. The marketed formulation is optimized for minimal drug substance absorption. A niclosamide solution has been developed that is expected to release the drug substance more readily and more reproducibly.

Camostat is approved for oral treatment of chronic pancreatitis and reflux oesophagitis in Japan. Camostat has been shown to effectively block viral replication in a SARS-CoV-2 animal model. Since the mechanisms of actions are different, it was hypothesized that a combination of both substances might have an additive or even synergistic effect in the treatment of COVID-19 patients.

This 3-part study is designed to investigate (1) safety and pharmacokinetics of single ascending doses of the new niclosamide solution after fasted and fed conditions, (2) the relative bioavailability of the niclosamide solution compared to the chewing tablet, and (3) safety and pharmacokinetics of the combination of niclosamide solution and camostat after multiple doses in healthy volunteers.


Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: Niclosamide Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Intervention Model Description:

Part A is a randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study with 3 planned cohorts.

Part B consists of two randomized, open-label, two-sequence, two-period crossover cohorts comparing the new niclosamide solution with the marketed chewing tablets.

Part C is a randomized, double-blinded, placebo-controlled multiple dose study investigating the safety and pharmacokinetics of the combination of niclosamide solution and camostat over a treatment period of 7 days.

Masking: Double (Participant, Investigator)
Masking Description: This three part study has double-blinded (placebo-controlled) and open-label parts.
Primary Purpose: Treatment
Official Title: A 3-part Study to Investigate the Safety and Pharmacokinetics of a Novel Niclosamide Solution as a Treatment Option for COVID-19 in Combination With Camostat
Actual Study Start Date : November 2, 2020
Estimated Primary Completion Date : May 31, 2021
Estimated Study Completion Date : May 31, 2021

Arm Intervention/treatment
Active Comparator: Part A: verum niclosamide

The SAD cohorts are planned as follows:

Cohort A1: 200 mg (fasted conditions) Cohort A2: 600 mg (fasted conditions) Cohort A3: 1600 mg (fasted and fed conditions)

Drug: Niclosamide
Niclosamide will be applied in various dosage steps, galenic preparations and in combination with camostat

Placebo Comparator: Part A: placebo to niclosamide

The SAD cohorts are planned as follows:

Cohort A1: placebo to niclosamide 200 mg (fasted conditions) Cohort A2: placebo to niclosamide 600 mg (fasted conditions) Cohort A3: placebo to niclosamide 1600 mg (fasted and fed conditions)

Drug: Placebo
placebo to the interventional drug

Active Comparator: Part B: verum as solution (niclosamide)
Two different crossover designs are chosen. Both are randomized, open-label, two-sequence, two periods crossover designs comparing the new niclosamide solution with the marketed chewing tablets. Planned doses are 1600 mg once daily (oral solution), 2000 mg once daily (chewing tablets) and 500 mg three times daily of both dosage forms.
Drug: Niclosamide
Niclosamide will be applied in various dosage steps, galenic preparations and in combination with camostat

Active Comparator: Part B: verum as chewing tablet (niclosamide)
Two different crossover designs are chosen. Both are randomized, open-label, two-sequence, two periods crossover designs comparing the new niclosamide solution with the marketed chewing tablets. Planned doses are 1600 mg once daily (oral solution), 2000 mg once daily (chewing tablets) and 500 mg three times daily of both dosage forms.
Drug: Niclosamide
Niclosamide will be applied in various dosage steps, galenic preparations and in combination with camostat

Active Comparator: Part C: verum (niclosamide and camostat)
Subjects will receive the combination of niclosamide solution (planned 500 mg three times daily) + camostat (600 mg three times daily) or placebo over a treatment period of 7 days. The dose of the niclosamide solution depends on the safety and pharmacokinetic results of Part A and B but will not exceed 500 mg three times daily.
Drug: Niclosamide
Niclosamide will be applied in various dosage steps, galenic preparations and in combination with camostat

Placebo Comparator: Part C: placebo to niclosamide and camostat
Subjects will receive the combination of niclosamide solution (planned 500 mg three times daily) + camostat (600 mg three times daily) or placebo over a treatment period of 7 days. The dose of the niclosamide solution depends on the safety and pharmacokinetic results of Part A and B but will not exceed 500 mg three times daily.
Drug: Placebo
placebo to the interventional drug




Primary Outcome Measures :
  1. Treatment emergent number of Adverse Events [ Time Frame: up to 14 days ]
    Assessment of severity of an AE will be based on CTCAE Version 5.0

  2. Maximum plasma concentration of niclosamide (µg/ml) [ Time Frame: from predose until 24 hours after intervention ]
    Measurement will start at Day 1

  3. Area Under the Plasma Concentration Time Curve from predose until last detectable concentration of niclosamide(AUC0-last) of niclosamide [µg/ml*h] [ Time Frame: from predose until 24 hours after intervention ]
    Measurement will start at Day 1


Secondary Outcome Measures :
  1. Food effect on maximum plasma concentration of niclosamide (µg/ml) [ Time Frame: from predose until 24 hours after intervention ]
    Measurement will start at Day 1 after a standard high fat breakfast

  2. Food effect on Area Under the Plasma Concentration Time Curve from predose until last detectable concentration of niclosamide (AUC0-last) [µg/ml*h] [ Time Frame: from predose until 24 hours after intervention ]
    Measurement will start at Day 1 after a standard high fat breakfast

  3. Maximum plasma concentration of niclosamide (µg/ml) at steady state after multiple dosing [ Time Frame: from predose until Day 9 ]
  4. Area Under the Plasma Concentration Time Curve between two dosing intervals (AUC tau ss) of niclosamide [µg/ml*h] at steady state after multiple dosing [ Time Frame: from predose until Day 9 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male or female subjects in good health as determined by past medical history
  • physical examination, vital signs and safety lab at screening
  • between 18 to 45 years of age

Exclusion Criteria:

  • Significant illness
  • pregnant or lactating women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04644705


Contacts
Layout table for location contacts
Contact: Frank D Wagner, Prof. Dr. med. +49 30 450 539 200 info@charite-research.org

Locations
Layout table for location information
Germany
Charité Research Organisation GmbH Recruiting
Berlin, Germany, 10117
Contact: Maximilian Posch, Dr. med.    +49 30 450 539 200    info@charite-research.org   
Sponsors and Collaborators
Charité Research Organisation GmbH
Bayer
Investigators
Layout table for investigator information
Principal Investigator: Maximilian Posch, Dr. med. Charité Research Organisation GmbH
Layout table for additonal information
Responsible Party: Charité Research Organisation GmbH
ClinicalTrials.gov Identifier: NCT04644705    
Other Study ID Numbers: 201767
First Posted: November 25, 2020    Key Record Dates
Last Update Posted: November 25, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Niclosamide
Anticestodal Agents
Antiplatyhelmintic Agents
Anthelmintics
Antiparasitic Agents
Anti-Infective Agents
Antinematodal Agents